Therapeutic targeting of HER-2 with monoclonal antibodies, like trastuzumab and pertuzumab, has revolutionized the therapy of breast cancer, leading to significant improvements in tumor response rates and patients’ survival [9,10,11]. This evidence concerns the gene ERBB2 and breast carcinoma.